# OnCo record paper-espac-4-gemcitabine-capecitabine-adjuvant-pancreatic-lancet-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-espac-4-gemcitabine-capecitabine-adjuvant-pancreatic-lancet-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-espac-4-gemcitabine-capecitabine-adjuvant-pancreatic-lancet-2017" ;
  schema:name "ESPAC-4: adjuvant gemcitabine plus capecitabine versus gemcitabine alone after resection of pancreatic cancer"@en ;
  schema:description "Adding the tablet capecitabine to gemcitabine after surgery for pancreatic cancer lengthened median survival by about two and a half months with little extra toxicity, giving patients who cannot manage FOLFIRINOX a better option than gemcitabine alone."@en ;
  schema:url <https://onco.cc/key-papers/paper-espac-4-gemcitabine-capecitabine-adjuvant-pancreatic-lancet-2017/> ;
  schema:dateModified "2026-09-21"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(16)32409-6>, <https://pubmed.ncbi.nlm.nih.gov/28129987/> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(16)32409-6> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Neoptolemos JP, Palmer DH, Ghaneh P, et al." ;
  onco:cancers <https://onco.cc/cancers/resectable-pdac/>, <https://onco.cc/cancers/pancreatic/> ;
  onco:drugs <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/capecitabine/> ;
  onco:journals <https://onco.cc/journals/lancet/> .